UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): October 29, 2020

KemPharm, Inc.
(Exact Name of Registrant as Specified in Its Charter)

Delaware	**001-36913**	**20-5894398**
(State or Other Jurisdiction of Incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**
1180 Celebration Boulevard, Suite 103, Celebration, FL		**34747**
(Address of Principal Executive Offices)		**(Zip Code)**

Registrant's Telephone Number, Including Area Code: (321) 939-3416

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	KMPH	None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Explanatory Note

This Amendment No. 1 on Form 8-K/A is an amendment to the Current Report on Form 8-K, or the Form 8-K, of KemPharm, Inc., a Delaware corporation, or KemPharm, filed with the Securities and Exchange Commission on October 29, 2020. Following the initial filing of the Form 8-K, KemPharm discovered that it had inadvertently checked the wrong item tag in the submission (Item 2.01, rather than Item 2.02). This Amendment No. 1 is being furnished for the sole purpose of correcting that item tag.

Item 2.02 Results of Operations and Financial Condition.

On October 29, 2020, KemPharm, Inc., a Delaware corporation, or KemPharm, issued a press release announcing its financial results for the third quarter ended September 30, 2020, as well as information regarding a conference call and live audio webcast with slide presentation to discuss these financial results. A copy of the press release and presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K. The information contained in the press release and presentation, furnished as Exhibits 99.1 and 99.2, respectively, shall not be deemed “filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and is not incorporated by reference into any of KemPharm's filings under the Securities Act of 1933, as amended, or the Securities Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press Release titled “KemPharm Reports Third Quarter 2020 Financial Results” dated October 29, 2020.
99.2	Presentation titled "Q3 2020 Results" dated October 29, 2020.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

KemPharm, Inc.

Date: October 29, 2020

By: /s/ R. LaDuane Clifton
R. LaDuane Clifton, CPA
Chief Financial Officer, Secretary and Treasurer

Exhibit 99.1

KemPharm Reports Third Quarter 2020 Financial Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET

Corporate and Regulatory Highlights:

- Announced expanded relationship with Corium through new consultation services agreement to provide revenue through March 2022
- Announced issuance of two additional U.S. patents governing KP415 and KP484
- Participated in mid-cycle review meeting with the FDA for the KP415 NDA; PDUFA date of March 2, 2021 re-affirmed
- Announced that its commercial partner for APADAZ®, KVK-Tech, Inc., entered into a collaboration agreement with Sure Med Compliance

Financial Highlights

- Reported Q3 2020 revenue of $1.9 million, derived primarily from consulting services
- Q3 2020 net loss of ($0.04) per basic share and diluted share compared to a net income of $0.09 per basic share and $0.06 per diluted share for Q3 2019
- Total cash, cash equivalents and restricted cash was $5.5 million at September 30, 2020

Celebration, FL – October 29, 2020 – KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today reported its financial results for the third quarter ended September 30, 2020.

"The third quarter was highlighted by several achievements which served to strengthen and diversify our business as momentum continues to build towards the anticipated March 2, 2021 action date (PDUFA) for KP415," said Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm. "Chief among these was the entry into an expanded consultation services agreement with Corium through which we are now collaborating with Corium to guide the product development and regulatory activities for certain current and potential future products in Corium's portfolio. Combined with our ongoing work providing commercial support to Corium for KP415, these work orders have the potential to provide KemPharm with service and other fees of up to $15.6 million through March 31, 2022."

Dr. Mickle continued, "These recent events and the numerous milestones expected prior to and following the KP415 PDUFA have created a drumbeat of excitement at KemPharm. As we look forward, there are multiple events that we believe will continue our momentum, including a commercial update from Corium regarding their plans for the potential commercial launch of KP415 in the second half of 2021, if approved. We are also looking ahead to the late-cycle review meeting with the FDA which is scheduled for December 1, 2020, if needed."

Dr. Mickle concluded, "We were also tracking the progress made by KVK-Tech, our commercial partner for APADAZ. KVK-Tech's collaboration with Sure Med Compliance has the potential to build greater prescriber awareness for APADAZ while focusing on providing education to physicians, pharmacies, and patients regarding responsible opioid therapy."

Q3 2020 Financial Results:

For Q3 2020, KemPharm reported revenue of $1.9 million, which was primarily derived from service fee revenue, as compared to Q2 2020 revenue of $6.9 million which is comprised of a $5.0 million milestone payment received based on the acceptance of the KP415 NDA by the FDA, $1.1 million from research and development services, $0.4 million of reimbursements revenue under the KP415 License Agreement and $0.4 million related to other consulting arrangements. Current consulting arrangements are expected to provide service fee revenue through March 2022.

KemPharm's net loss for Q3 2020 was ($3.0 million), or ($0.04) per basic share and diluted share, compared to net income of $3.1 million, or $0.09 per basic share and $0.06 per diluted share for the same period in 2019. Net loss for Q3 2020 was driven primarily by operating loss of ($1.2 million) and net interest expense and other items of ($1.7 million). The net operating loss of ($1.2 million) for Q3 2020 was a change of $4.4 million compared to net operating income of $3.2 million in the same period in 2019, which was primarily due to a decrease in revenue of $9.5 million, primarily due to the upfront payment received under the KP415 License Agreement of $10.0 million in Q3 2019, partially offset by a decrease in royalty and direct contract acquisition costs of $1.0 million related to the upfront payment in Q3 2019, a decrease in research and development expenses of $1.9 million and a decrease in general and administrative expenses of $2.2 million.

As of September 30, 2020, total cash, cash equivalents and restricted cash was $5.5 million, which was a decrease of $1.1 million compared to June 30, 2020. Based on the Company's current operating forecast, the Company believes that its expected revenues and existing resources are sufficient to continue operations past the potential PDUFA date for the KP415 NDA and up to the debt maturity date of March 31, 2021.

Conference Call Information:

KemPharm will host a conference call and live audio webcast with slide presentation on Thursday, October 29, 2020, at 4:30 p.m. ET, to discuss its corporate and financial results for the third quarter 2020. Interested participants and investors may access the conference call by dialing either:

- (866) 395-2480 (U.S.)
- (678) 509-7538 (international)
- Conference ID: 1696738

An audio webcast with slide presentation will be accessible via the Investor Relations section of the Company's website, http://investors.kempharm.com/. An archive of the webcast and presentation will be available for 90 days beginning at approximately 5:30 p.m. ET, on October 29, 2020.

About KemPharm:

KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT® (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT® technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm's prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm's co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com or connect with us on Twitter, LinkedIn, Facebook and YouTube.

Caution Concerning Forward Looking Statements:

This press release may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation our proposed development and commercial timelines, and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements, including the timing of the PDUFA date and potential FDA approval of the KP415 NDA, the potential commercial launch of KP415, the expectations regarding continued research and development services revenue, the potential clinical benefits of KP415 or any of the Company's product candidates, the potential initiation or timeline for the development of any of our product candidates, cash runway, and the potential timeline to complete a debt restructuring, if at all, are based on information currently available to KemPharm and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning KemPharm's business are described in detail in KemPharm's Annual Report on Form 10-K for the year ended December 31, 2019, KemPharm's Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, and KemPharm's other Periodic and Current Reports filed with the Securities and Exchange Commission. KemPharm is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

KemPharm Contacts:

Jason Rando / Maureen McEnroe
Tiberend Strategic Advisors, Inc.
212-375-2665 / 2664
jrando@tiberend.com
mmcenroe@tiberend.com

KEMPHARM, INC.
UNAUDITED CONDENSED STATEMENTS OF OPERATIONS
(in thousands, except share and per share amounts)

	Three months ended September 30,		Nine months ended September 30,	
	2020	**2019**	**2020**	**2019**
Revenue	$ 1,925	$ 11,463	$ 10,922	$ 11,463
Operating expenses:				
Royalty and direct contract acquisition costs	—	1,000	1,305	1,000
Research and development	1,709	3,616	5,789	16,950
General and administrative	1,429	3,613	5,393	9,440
Severance expense	—	—	830	—
Total operating expenses	3,138	8,229	13,317	27,390
(Loss) income from operations	(1,213)	3,234	(2,395)	(15,927)
Other (expense) income:				
Interest expense related to amortization of debt issuance costs and discount	(578)	(371)	(1,723)	(981)
Interest expense on principal	(1,163)	(1,208)	(3,620)	(3,669)
Fair value adjustment related to derivative and warrant liability	(137)	1,351	(65)	1,783
Interest and other income (expense), net	48	60	(135)	295
Total other expenses	(1,830)	(168)	(5,543)	(2,572)
(Loss) income before income taxes	(3,043)	3,066	(7,938)	(18,499)
Income tax benefit (expense)	34	(3)	34	14
Net (loss) income	$ (3,009)	$ 3,063	$ (7,904)	$ (18,485)
Net (loss) income per share of common stock:				
Basic	$ (0.04)	$ 0.09	$ (0.13)	$ (0.65)
Diluted	$ (0.04)	$ 0.06	$ (0.13)	$ (0.65)
Weighted average number of shares of common stock outstanding:				
Basic	70,809,221	30,126,704	60,718,998	28,417,450
Diluted	70,809,221	31,672,149	60,718,998	28,417,450

KEMPHARM, INC.
CONDENSED BALANCE SHEETS
(in thousands, except share and par value amounts)

	September 30, 2020 (unaudited)	December 31, 2019
Assets		
Current assets:		
Cash and cash equivalents	$ 5,267	$ 3,217
Accounts and other receivables	2,202	1,865
Prepaid expenses and other current assets	675	1,552
Total current assets	8,144	6,634
Property and equipment, net	1,079	1,471
Operating lease right-of-use assets	1,357	1,537
Restricted cash	186	338
Other long-term assets	438	527
Total assets	$ 11,204	$ 10,507
Liabilities and stockholders' deficit		
Current liabilities:		
Accounts payable and accrued expenses	$ 4,347	$ 4,911
Current portion of convertible notes	65,920	—
Current portion of operating lease liabilities	318	284
Other current liabilities	213	236
Total current liabilities	70,798	5,431
Convertible notes, less current portion, net	—	77,343
Derivative and warrant liability	184	120
Operating lease liabilities, less current portion	1,673	1,901
Loans payable	781	—
Other long-term liabilities	95	168
Total liabilities	73,531	84,963
Commitments and contingencies (Note D)		
Stockholders’ deficit:		
Preferred stock:		
Series A convertible preferred stock, $0.0001 par value, 9,578 shares authorized, 9,577 shares issued and no shares outstanding as of September 30, 2020 (unaudited) and December 31, 2019	—	—
Series B-1 convertible preferred stock, $0.0001 par value, 1,576 shares authorized, 1,576 shares issued and no shares outstanding as of September 30, 2020 (unaudited) and December 31, 2019	—	—
Series B-2 convertible preferred stock, $0.0001 par value, 27,000 shares authorized, no shares issued or outstanding as of September 30, 2020 (unaudited) and December 31, 2019	—	—
Undesignated preferred stock, $0.0001 par value, 9,961,846 shares authorized, no shares issued or outstanding as of September 30, 2020 (unaudited) and December 31, 2019	—	—
Common stock, $0.0001 par value, 250,000,000 shares authorized, 72,514,304 shares issued and outstanding as of September 30, 2020 (unaudited); 36,350,785 shares issued and outstanding as of December 31, 2019	7	4
Additional paid-in capital	191,284	171,254
Accumulated deficit	(253,618)	(245,714)
Total stockholders' deficit	(62,327)	(74,456)
Total liabilities and stockholders' deficit	$ 11,204	$ 10,507


KemPharm
Q3 2020 Results
October 29, 2020

Cautionary Note Regarding Presentation Information

This presentation contains forward-looking statements, including statements regarding the potential approval timing for KP415, the potential label for KP415, the royalty or milestone payments under our license agreement with Gurnet Point Capital, the duration of our cash runway following the transactions described in this presentation, our plans to develop and commercialize our product candidates, our planned clinical trials for our prodrug product candidates, the timing of and our ability to obtain and maintain regulatory approvals for our product candidates, including expectations about our ability to use the 505(b)(2) pathway and expedited FDA review, the clinical utility of our product candidates, the status of the APADAZ® commercialization, the plans and capabilities of our collaborators, our ability to perform under any collaboration or consulting arrangement, our intellectual property position, and our ability or the timing to restructure our outstanding debt or our balance sheet or re-list to the Nasdaq, if at all. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this presentation represent our views as of the date of this presentation. Risks concerning KemPharm's business are described in detail in KemPharm's Annual Report on Form 10-K for the year ended December 31, 2019, and KemPharm's other Periodic and Current Reports filed with the Securities and Exchange Commission. We are under no obligation to, and expressly disclaim any such obligation to, update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

Q3 2020 Results Call Participants

- **Travis Mickle, Ph.D.** – President & Chief Executive Officer
- **R. LaDuane Clifton, CPA** – Chief Financial Officer, Secretary & Treasurer

KemPharm: Q3 2020 and Recent Highlights

KP415 Updates

- Held mid-cycle review meeting w/ FDA on Aug 13, affirmed PDUFA date of Mar 2, 2021, no safety issues raised at that time
  - Late-cycle review meeting to be held on Dec 1, if needed
- Two additional U.S. patents governing SDX products issued, adds 5 years (2037 expiry)

Q3 2020 Financial Results

- Revenue of $1.9M from consulting services
- Total cash and investments was $5.5M at Sep 30, 2020, decrease of $1.1M compared to Jun 30, 2020
- Based on current operating forecast, projected cash runway extends up to the debt maturity date of Mar 31, 2021

Partnership Updates

- New consultation services agreement with **Corium** for projects other than KP415 with potential revenue through Mar 2022
- Announced collaboration between **KVK-Tech** and Sure Med Compliance for APADAZ® pilot program in Alabama

Improving Financial Position

- Optimized restructuring transaction(s) and subsequent potential reverse stock split could lead to re-listing on Nasdaq
- Project cash burn remains at ~$1M/quarter
- Balance sheet restructuring process is ongoing, with multiple options under consideration

KP415 Updates

- Held KP415 NDA mid-cycle review meeting with FDA on Aug 13, 2020
  - FDA re-affirmed KP415 PDUFA date of Mar 2, 2021, no substantive issues or safety concerns were raised
  - Late-cycle review meeting to be held on Dec 1, 2020 (if necessary)
- Corium, Inc. is leading all commercial activities for KP415
  - Corium continues to build out its team and its KP415 commercial launch plan; manufacturing validation well underway
  - If approved, target launch date for KP415 in H2 2021
  - KemPharm and Corium to co-host analyst/investor call to provide overview of commercial plans and market dynamics; date to be announced soon

Corium, Inc. – An Expanding Relationship

- New consultation services agreement between KemPharm and Corium announced on Oct 5, 2020
  - Agreement encompasses product development and regulatory activities for certain current and potential future products in Corium's portfolio
  - New activities are above and beyond KemPharm's ongoing commercial support activities for KP415
- Combined with ongoing revenues from ongoing KP415 commercial support, expanded relationship provides for KemPharm to receive service fees of up to **$15.6M** through Mar 31, 2022
  - Extends related revenue stream more than a year past the KP415 PDUFA date; possibly longer if extended

APADAZ® – KVK-Tech/Sure Med Collaboration

- Announced collaboration between KVK-Tech and Sure Med Compliance on Sep 10, 2020
  - Newly announced program known as Perspectives in Care®, combines Sure Med's opioid prescribing compliance tools with education and research to create a more-informed opioid prescribing environment
  - Provides education to physicians, pharmacies, and patients regarding responsible opioid therapy
  - Introduces APADAZ as a responsible alternative for opioid therapy, where appropriate
  - Collects utilization and patient outcome data related to the use of APADAZ as a replacement for branded and generic prescription opioid products
- Pilot program will launch in Alabama on **Dec 1, 2020**, with additional states expected to follow
- 2019 HC/APAP utilization in Alabama was more than 129M tablets

Special Meeting to Authorize Potential Reverse Stock Split

- Special meeting of stockholders has been rescheduled for Nov 17, 2020 at 8:00 a.m. ET.
- KemPharm is seeking authorization for a potential reverse stock split of the Company's common stock; reverse stock split will only be made effective if our Board determines it is in the best interest of the Company and of shareholders
- Authorization of a potential reverse stock split will be for twelve months following the Special Meeting, if approved.
- To re-list on the NASDAQ Capital Market, KMPH must address two items:
  - Bid price of at least $4.00
  - Stockholders' equity of $5M (compared to stockholders' deficit of ($62.3M) as of Sep 30, 2020)
- If stockholders' equity is not increased to at least $5M, then a reverse split would not enable re-listing on Nasdaq

Special Meeting to Authorize Potential Reverse Stock Split

- Reverse split range between 1-for-3 and 1-for-40 intentionally broad
  - It is impossible to predict at this time what ratio will be needed to reach a bid price of greater than $4.00; we will seek to optimize this ratio
- The administrative process to authorize a reverse stock split is lengthy
  - Prior authorization would enable moving quickly on a transaction that requires re-listing on NASDAQ, but only if such transaction is in the best interest of the Company and shareholders
- A reverse stock split does not by itself create dilution, but the various options for debt restructuring require varying degrees of either equity or asset dilution
  - We seek to minimize both the cost of capital and dilution
- If possible, re-listing KMPH's common stock on NASDAQ could provide access to a larger institutional investor base and opportunities to capitalize on upcoming KP415 milestones

Q3 2020 Financial Results

- Revenue and Net Income (Loss)
  - Revenue of $1.9M, comprised of services revenue under the Corium consulting arrangement, compared to Q2 2020 service revenue of $1.9M
  - Q3 2020 is the fifth sequential quarter of services revenue
  - Net loss of ($3.0M), or ($0.04) per basic and diluted share, compared to net income of $3.1M, or $0.09 per basic share and $0.06 per diluted share for Q3 2019
- Expense
  - Q3 2020 operating loss of ($1.2M), which is a change of $4.4M compared to net operating income of $3.2M in Q3 2019, primarily driven by a decrease in revenue of $9.5M, and partially offset by decreases in operating expenses of $5.1M
  - R&D expenses were $1.7M, a 53% reduction compared to Q3 2019
  - G&A expenses were $1.4M, a 60% reduction compared to Q3 2019

Q3 2020 Balance Sheet Update

- As of Sep 30, 2020, total cash[1] was $5.5M, a decrease of $1.1M compared to Jun 30, 2020; forecasted cash burn rate of ~$1M/quarter
  - Based on operating forecast, expected revenues and existing resources, cash runway expected to up to the debt maturity date of Mar 31, 2021
- Total debt, net, of $65.9M at Sep 30, 2020, vs. $67.3M at Jun 30, 2020
  - Reduction of $1.4M due to Deerfield exchanges of $3.1M during Q3 2020, offset by interest added to principal of $1.2M and amortization of debt discount and issuance costs of $0.6M
- As of Sep 30, 2020, stockholders' deficit was ($62.3M)
- As of Oct 28, 2020, 72,544,837 common shares outstanding

1 - Includes cash, cash equivalents and restricted cash.

Next Steps on Improving Financial Position

- Phase 2 of debt restructuring remains one of our highest priorities; goal to complete prior to the KP415 PDUFA date
- We continue to work with our financial advisors to determine the best pathway to restructure the debt and optimize the cost of capital/dilution; options include:
  - Debt to equity conversion
  - New corporate debt with extended maturity
  - Debt repayment from potential KP415 milestone, secondary offering, or royalty financing
- Likely outcome will be a combination of these options; the cost of capital will be dynamic approaching KP415 catalysts and Mar 31, 2021 debt maturity
- A secondary goal of the process is to address our current stockholder's deficit and be positioned to meet the initial listing requirements for re-listing on the Nasdaq

KemPharm: Next Steps and Outlook

KP415 NDA - FDA has set KP415 PDUFA date of Mar 2, 2021 - KP415 Late-Cycle Review meeting with FDA scheduled for Dec 1, 2020, if needed - KP415 approval milestones up to $48M	**Improved Financial Position** - Based on current operating forecast, projected cash runway extends up to the debt maturity date of Mar 31, 2021 - Expanded services revenue and careful expense management remains in focus - Debt restructuring process active, still potential to address pre-PDUFA
KP415 Commercial Progress - KemPharm working with Corium on commercial supply for potential mid-2021 launch - Corium and KemPharm to provide KP415 commercial and ADHD market update; date to be announced soon	**Beyond KP415** - Expanded Corium services agreement adds additional revenue - Actively preparing KP879 IND for submission to FDA - KVK-Tech/Sure Med collaboration for APADAZ, Perspectives in Care program set to launch on Dec 1, 2020 in Alabama

Q3 2020 Results

October 29, 2020